CEO Dr. Shankar Musunuri to be Featured as a Panelist at Xconomy’s Xcelerating Life Sciences Virtual Event Discussing The P...
28 November 2020 - 12:08AM
Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on
discovering, developing, and commercializing transformative
therapies to cure blindness diseases, today announced Dr. Shankar
Musunuri, Chairman, CEO, and Co-Founder of Ocugen, will speak on
“The Promise of Cell & Gene Therapies: Regulatory and
Reimbursement Roadblocks” at Xconomy’s Xcelerating Life Sciences
New York & Philadelphia Virtual Event on December 3 at 10:30
a.m. This panel will be moderated by Theresa Lavoie, Principal,
Fish & Richardson and also feature panelists, Greg White,
Senior Director, Global Market Access Policy – Janssen,
Pharmaceutical Companies and Snehal Naik, Global Regulatory Affair-
Advanced Therapies, Janssen R&D.
|
|
Presentation Details: |
Title: |
“The Promise of Cell & Gene Therapies: Regulatory and
Reimbursement Roadblocks” |
Date: |
Thursday, December 3, 2020 |
Time: |
10:30 AM (ET) |
Location: |
Digital |
Register: |
https://xconomy.com/xcelerating-life-sciences-new-york/register-now-2/ |
|
|
About Ocugen, Inc.Ocugen, Inc. is a
biopharmaceutical company focused on discovering, developing, and
commercializing transformative therapies to cure blindness
diseases. Our breakthrough modifier gene therapy platform has the
potential to treat multiple retinal diseases with one drug – “one
to many” and our novel biologic product candidate aims to offer
better therapy to patients with underserved diseases such as wet
age-related macular degeneration, diabetic macular edema, and
diabetic retinopathy. For more information, please visit
www.ocugen.com.
Cautionary Note on Forward-Looking
StatementsThis press release contains
forward-looking statements within the meaning of The Private
Securities Litigation Reform Act of 1995, which are subject to
risks and uncertainties. We may, in some cases, use terms such as
“predicts,” “believes,” “potential,” “proposed,” “continue,”
“estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,”
“could,” “might,” “will,” “should” or other words that convey
uncertainty of future events or outcomes to identify these
forward-looking statements. Such statements are subject to numerous
important factors, risks and uncertainties that may cause actual
events or results to differ materially from our current
expectations. These and other risks and uncertainties are more
fully described in our periodic filings with the Securities and
Exchange Commission (the “SEC”), including the risk factors
described in the section entitled “Risk Factors” in the quarterly
and annual reports that we file with the SEC. Any forward-looking
statements that we make in this press release speak only as of the
date of this press release. Except as required by law, we assume no
obligation to update forward-looking statements contained in this
press release whether as a result of new information, future events
or otherwise, after the date of this press release.
Corporate Contact:Ocugen, Inc.Sanjay
SubramanianChief Financial OfficerIR@Ocugen.com
Media Contact:
LaVoieHealthScience Katie
Gallagherkgallagher@lavoiehealthscience.com+1 617-792-3937
Ocugen (NASDAQ:OCGN)
Historical Stock Chart
From Apr 2024 to May 2024
Ocugen (NASDAQ:OCGN)
Historical Stock Chart
From May 2023 to May 2024